Antibodies that recognize cutting edge within the TGF-β activation controlling region
US8198412B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Aug 13, 2010 |
| Grant date | Jun 12, 2012 |
| Priority date | — |
| Expiry date | Aug 13, 2030 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/6893
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
It is an object of the present invention to provide antibodies capable of detecting an active TGF-β generation reaction that is specific to pathogenesis, tissues, or isoforms. The present invention provides antibodies against an LAP fragment (or latent TGF-β) generated as a result of generation of active form of human TGF-β1, human TGF-β2 and human TGF-β3. The antibodies are able to specifically recognize respective cutting edges within protease cleavage sites existing in the region from the amino acid residue glycine at position 51 to the amino acid residue arginine at position 110 of human TGF-β1, and corresponding regions of human TGF-β2 and human TGF-β3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.